# Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

> **NCT03261999** · PHASE3 · COMPLETED · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 144 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Leuprolide Mesylate

## Key facts

- **NCT ID:** NCT03261999
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2018-11-19
- **Final completion:** 2019-02-01
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261999, "Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03261999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*